Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development ...

The American College of Gastroenterology has published its first clinical guideline on the diagnosis and management of ...

Stephanie Seban received a misdiagnosis of her own stage 4 breast cancer more than a decade ago, but after taking her health ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...

gastric or gastro-oesophageal junction adenocarcinoma in adults that is: locally advanced (has spread to nearby tissue), unresectable (cannot be surgically removed) or metastatic (has spread to other ...

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in ...

Gastric cancer, or stomach cancer, is a type of cancer that begins in the mucus-producing cells on the inside lining of the stomach. The most common type of stomach cancer is adenocarcinoma.